Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN. https://www.nasdaq.com/articles/next-gen-cancer-therapies-could-spark-upside-for-astrazeneca-stock